A1CF | APOBEC1 complementation factor | | | | | | Tissue enhanced |
ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
AK4 | Adenylate kinase 4 | Enzymes Mitochondrial proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | Enzymes
| | | | | Tissue enhanced |
ALX1 | ALX homeobox 1 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
ANLN | Anillin, actin binding protein | | | | | | Tissue enhanced |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ANXA13 | Annexin A13 | Plasma proteins
| | | | | Tissue enhanced |
AOX1 | Aldehyde oxidase 1 | Enzymes Plasma proteins
| | | | | Tissue enhanced |
ARHGAP28 | Rho GTPase activating protein 28 | | | | | | Tissue enhanced |
ASB9 | Ankyrin repeat and SOCS box containing 9 | | | | | | Tissue enhanced |
ASS1 | Argininosuccinate synthase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
AUNIP | Aurora kinase A and ninein interacting protein | | | | | | Tissue enhanced |
BAG2 | BCL2-associated athanogene 2 | Plasma proteins
| | | | | Tissue enhanced |
BARX2 | BARX homeobox 2 | Transcription factors
| | | | | Tissue enhanced |
BASP1 | Brain abundant, membrane attached signal protein 1 | Cytoskeleton related proteins Plasma proteins Transporters
| | | | | Tissue enhanced |
BCL2L14 | BCL2-like 14 (apoptosis facilitator) | | | | | | Tissue enhanced |
BRIP1 | BRCA1 interacting protein C-terminal helicase 1 | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
C17orf53 | Chromosome 17 open reading frame 53 | | | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
CALB2 | Calbindin 2 | Plasma proteins
| | | | | Tissue enhanced |
CASC5 | Cancer susceptibility candidate 5 | Cancer-related genes Disease related genes Plasma proteins
| | | | | Tissue enhanced |
CAV1 | Caveolin 1, caveolae protein, 22kDa | Cancer-related genes Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CBS | Cystathionine-beta-synthase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
CCDC112 | Coiled-coil domain containing 112 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCDC113 | Coiled-coil domain containing 113 | | | | | | Tissue enhanced |
CCDC15 | Coiled-coil domain containing 15 | | | | | | Tissue enhanced |
CCDC181 | Coiled-coil domain containing 181 | | | | | | Tissue enhanced |
CCDC40 | Coiled-coil domain containing 40 | Disease related genes
| | | | | Tissue enhanced |
CCNB2 | Cyclin B2 | Cancer-related genes Plasma proteins
| | | | | Tissue enhanced |
CCNB3 | Cyclin B3 | | | | | | Tissue enhanced |
CD2 | CD2 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD79B | CD79b molecule, immunoglobulin-associated beta | Cancer-related genes CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CDC20 | Cell division cycle 20 | Cancer-related genes Plasma proteins
| | | | | Tissue enhanced |
CDC45 | Cell division cycle 45 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CDH2 | Cadherin 2, type 1, N-cadherin (neuronal) | CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CDKL5 | Cyclin-dependent kinase-like 5 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
CGNL1 | Cingulin-like 1 | Disease related genes
| | | | | Tissue enhanced |
CLDN2 | Claudin 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
CLGN | Calmegin | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
COL4A2 | Collagen, type IV, alpha 2 | Cancer-related genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
COL8A1 | Collagen, type VIII, alpha 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CRYAB | Crystallin, alpha B | Cancer-related genes Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CSTA | Cystatin A (stefin A) | Cancer-related genes Disease related genes Plasma proteins
| | | | | Tissue enhanced |
CTH | Cystathionase (cystathionine gamma-lyase) | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
DKK3 | Dickkopf WNT signaling pathway inhibitor 3 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
DPEP1 | Dipeptidase 1 (renal) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
DTL | Denticleless E3 ubiquitin protein ligase homolog (Drosophila) | | | | | | Tissue enhanced |